Skip to main content

New story in Health from Time: Moderna’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study



Earlier today, the biotech company Moderna reported positive results from a phase 1 study of its experimental COVID-19 vaccine, which was was among the first to begin testing in healthy human volunteers in mid-March.

The study, led by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of people who recovered from infections.

The phase 1 study is actually not designed to measure effectiveness of the vaccine—it is is focused primarily on safety. Nevertheless, the hints of efficacy emerging from the trial are encouraging. The level of antibodies seen in the participants show that the vaccine can attract and awaken the body’s immune response to mount a defense against SARS-CoV-2. The data also hinted that the higher doses prompted stronger immune responses.

In addition, the company reports that in a preliminary analysis, antibodies from eight of the participants (four given the low dose and four given the medium dose) appeared to neutralize the virus in the lab.

In the phase 1 study, the participants were all healthy volunteers aged 18 to 55 years. Those in the low- and medium-dose groups received two doses about a month apart, in order to properly prime the immune system for the most robust response. People in the highest dose group received only one inoculation. The results will likely be analyzed and reported in a scientific publication in coming weeks.

Based on these results, the phase 2 study, which the Food and Drug Administration (FDA) has cleared, will enroll around 600 healthy volunteers, will include just two doses—one that is slightly higher than the lowest dose, as well as the medium dose, since these appear to be sufficient to generate a relatively strong immune response. The company expects those trials to begin in June, and may include those at higher risk of exposure to SARS-CoV-2, such as health care workers. Those studies will determine which dose will be tested in the final, phase 3 studies that could begin as early as July. Based on the urgent need for a vaccine against COVID-19, on May 12 the FDA gave Moderna’s vaccine fast track status, which would expedite the regulatory agency’s review process.

These findings, though still early, are a validation of Moderna’s technology, which veers from the traditional vaccine design that generally depend on snippets of viral proteins or inactivated virus to activate the immune system. Moderna’s vaccine is made of mRNA from the virus, the genetic material that codes for proteins; after inoculation, it can prompt the body’s immune cells to recognize it as foreign and launch attacks against it. The company has been developing mRNA vaccines against a number of other disease, including respiratory syncytial virus, Zika and influenza.

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.
Read more

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp
Read more

New story in Health from Time: What We Don’t Know About COVID-19 Can Hurt Us

Countries around the world have introduced stringent control measures to stop COVID-19 outbreaks growing, but now many find themselves facing the same situation again. From Melbourne to Miami, the relaxation of measures had led to increasing flare-ups, which in some places has already meant reclosing schools, businesses or travel routes. Within the U.S. and among different countries , places with wildly varying public-health policies have experienced wildly diverse outcomes. Most ominously, infections are rising rapidly in many places where they once were falling. So how do countries avoid an indefinite, unsustainable, cycle of opening and closing society? What is needed to prevent a future of strict social distancing and closed borders? To escape this limbo, we need to know more about each step in the chain of infection: why some people are more susceptible or have more symptoms, how our interactions and surroundings influence risk, and how we can curb the impact of the re
Read more